Profile data is unavailable for this security.
About the company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
- Revenue in USD (TTM)449.00k
- Net income in USD-19.85m
- Incorporated1996
- Employees12.00
- LocationCyclacel Pharmaceuticals Inc200 Connell Dr Ste 1500BERKELEY HEIGHTS 07922-2811United StatesUSA
- Phone+1 (908) 517-7330
- Fax+1 (866) 271-3466
- Websitehttps://cyclacel.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Finch Therapeutics Group Inc | 0.00 | -16.28m | 2.04m | 18.00 | -- | 0.1071 | -- | -- | -10.14 | -10.14 | 0.00 | 11.86 | 0.00 | -- | -- | -- | -25.22 | -- | -28.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
Soligenix Inc | 699.21k | -7.01m | 2.08m | 13.00 | -- | 1.81 | -- | 2.98 | -11.83 | -11.83 | 1.16 | 1.17 | 0.073 | -- | 4.17 | 53,785.38 | -73.17 | -75.40 | -2,448.34 | -154.32 | 9.46 | 22.83 | -1,002.55 | -620.02 | -- | -- | 0.7959 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
Azitra Inc | 572.70k | -12.40m | 2.18m | 10.00 | -- | 0.504 | -- | 3.81 | -86.11 | -86.11 | 1.48 | 4.50 | 0.0977 | -- | 11.54 | 57,270.00 | -200.61 | -- | -287.43 | -- | -- | -- | -2,053.34 | -- | -- | -129.02 | 0.0085 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
Aptevo Therapeutics Inc | 0.00 | -27.31m | 2.25m | 40.00 | -- | 0.0322 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
Cyclacel Pharmaceuticals Inc | 449.00k | -19.85m | 2.36m | 12.00 | -- | -- | -- | 5.25 | -21.99 | -21.99 | 0.4636 | -1.67 | 0.0318 | -- | 0.1204 | -- | -139.57 | -57.58 | -314.22 | -69.81 | -- | -- | -4,386.86 | -18,789.29 | -- | -128.51 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
Eloxx Pharmaceuticals Inc | 0.00 | -20.48m | 2.36m | 18.00 | -- | -- | -- | -- | -9.06 | -9.06 | 0.00 | -6.53 | 0.00 | -- | -- | 0.00 | -124.43 | -115.27 | -- | -155.33 | -- | -- | -- | -- | -- | -16.69 | -- | -- | -- | -- | 45.95 | -- | -22.56 | -- |
Aclarion Inc | 60.05k | -6.13m | 2.38m | 6.00 | -- | 0.83 | -- | 39.71 | -7.41 | -7.41 | 0.0341 | 0.3502 | 0.0215 | -- | 3.50 | 10,008.33 | -219.26 | -- | -337.53 | -- | -29.49 | -- | -10,203.20 | -- | -- | -- | 0.211 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
Regen BioPharma Inc | 236.58k | -851.69k | 2.47m | 1.00 | -- | -- | -- | 10.44 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
Cingulate Inc | 0.00 | -22.50m | 2.48m | 13.00 | -- | 0.5252 | -- | -- | -22.66 | -22.66 | 0.00 | 0.6419 | 0.00 | -- | -- | 0.00 | -355.56 | -- | -1,198.96 | -- | -- | -- | -- | -- | -- | -33.88 | 0.0054 | -- | -- | -- | -33.14 | -- | -- | -- |
Qrons Inc | 0.00 | -763.52k | 2.53m | 2.00 | -- | -- | -- | -- | -0.0562 | -0.0562 | 0.00 | -0.1078 | 0.00 | -- | -- | 0.00 | -18,782.78 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -19.02 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
SenesTech Inc | 1.38m | -7.51m | 2.55m | 25.00 | -- | 0.5524 | -- | 1.85 | -15.21 | -15.21 | 0.7189 | 0.8961 | 0.2718 | 0.939 | 13.29 | 55,000.00 | -148.36 | -118.53 | -178.99 | -140.61 | 42.33 | 39.40 | -545.82 | -1,357.86 | 5.69 | -- | 0.0378 | -- | 17.08 | 32.06 | 20.47 | -- | -9.02 | -- |
Exicure Inc | 500.00k | -13.34m | 2.61m | 6.00 | -- | 1.18 | -- | 5.21 | -1.56 | -1.56 | 0.0582 | 0.2551 | 0.0289 | -- | -- | 83,333.34 | -76.97 | -41.52 | -91.14 | -55.78 | -- | -- | -2,667.20 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
Entero Therapeutics Inc | 0.00 | -6.44m | 2.65m | 15.00 | -- | 0.1339 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Renaissance Technologies LLCas of 31 Mar 2024 | 20.84k | 1.42% |
Point72 Asset Management LPas of 31 Mar 2024 | 15.33k | 1.05% |
Acadian Asset Management LLCas of 31 Mar 2024 | 14.29k | 0.98% |
UBS Securities LLCas of 31 Mar 2024 | 4.84k | 0.33% |
Tower Research Capital LLCas of 31 Mar 2024 | 4.19k | 0.29% |
McIlrath & Eck LLCas of 31 Mar 2024 | 832.00 | 0.06% |
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 126.00 | 0.01% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 80.00 | 0.01% |
Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 33.00 | 0.00% |
SignatureFD LLCas of 31 Mar 2024 | 20.00 | 0.00% |